Thermo Finnigan, Paradigm Ink Metabolomics Partnership | GenomeWeb

NEW YORK, Nov. 6 — A division of Thermo Electron and Paradigm Genetics have formed a partnership to design new technologies for use in metabolomics, also known as the study of the interactions between small molecules, the companies said on Tuesday.

The companies plan to use chromatography and mass spectrometry systems to develop a new way to identify and validate metabolite biomarkers that they believe may be useful in drug discovery. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.